Appointment to the Board

4 September 2014

Source BioScience plc

("Source BioScience" or "the Group")

Appointment to the Board

Source BioScience plc (LSE: SBS) the international laboratory services and products business, announces that Tim Metcalfe will join the Board as Group Finance Director with immediate effect. Tim succeeds Rob Bakewell who has left the Group to pursue other opportunities.

Tim is an experienced financial professional and has held senior roles in both private and listed companies, in the retail, manufacturing and IT sectors. Prior to joining Source BioScience, Tim was Group Finance Director at TFM Networks, a provider of telecoms and data management solutions. Tim holds a BA (Hons) from Nottingham University and qualified as a Chartered Accountant in 1995, spending twelve years with KPMG prior to moving into industry.

Laurie Turnbull, Chairman, said: "I would like to thank Rob for his valuable contribution over the past nine years and for ensuring an orderly handover to Tim. We wish him well in his new venture.

"I am delighted to welcome Tim to the Board. His substantial international accounting and finance experience, in a range of large, multinational companies, will be invaluable as we continue with the implementation of the Group's growth strategy and the expansion of our operations outside of the UK."

No further information is required to be disclosed pursuant to paragraph 9.6.13 of the Listing Rules.

--- ENDS ---

For further information, please contact:

Source BioScience plc

Dr Nick Ash, CEO

Tel: +44 (0)115 973 9010

Email: [email protected]

www.sourcebioscience.com

For investor and media enquiries:

N+1 Singer (Financial Advisor, Sponsor and Broker)

Aubrey Powell / James White

Tel: +44 (0)207 496 3000

www.n1singer.com

Instinctif Partners (PR Agency)

Melanie Toyne-Sewell/Jen Lewis/Emma Barlow

Tel: +44 (0)207 457 2020

Email: [email protected]

About Source BioScience:

Source BioScience is a trusted provider of state-of-the-art products and services to the healthcare and clinical, life and applied scientific and biopharma industries. It is an international business with centres in four countries and customers in over 90 countries. The Group offers a complementary portfolio of products and services that share common technologies, lab processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These products and services are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange (LSE: SBS).